Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to
carfilzomib and dexamethadone for RRMM patients who have been previously exposed to
lenalidomide combination therapies.